BioNTech

Working to transform how cancer is treated

At BioNTech, our mission is to translate science into survival by harnessing the full power of the immune system. We are committed to transforming how cancer is treated. Our ambition is to develop medicines that work together to treat cancer from many angles — training the immune system to recognize cancer more effectively, addressing multiple disease drivers, and targeting tumor cells with precision. Our diversified oncology portfolio combines complementary approaches designed to address the full spectrum of cancer, from early-stage disease with high risk of recurrence to advanced and metastatic cancers.   

Redefining what is possible in cancer treatment can only happen by fully partnering with patients and organizations ​​like Susan G. Komen. BioNTech puts the patient first at every stage of our work.  We listen – and act based on what we learn – to make the path to life-changing treatments easier and more successful for as many people as possible. 

Our Partnership
We are proud to partner with Susan G. Komen on initiatives such as the Breast Cancer Breakthroughs series, to ensure patients are kept up to date on the latest treatment advancements and development progress. Through this partnership, expert-led video panels and podcasts bring together researchers and patient advocates to educate the breast cancer community about clinical research and new therapeutics. 

About BioNTech
BioNTech is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a strategic set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, Pfizer and Regeneron. 

For more information, please visit www.BioNTech.com.